US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
US20040049014A1
(en)
*
|
1988-12-28 |
2004-03-11 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
ES2126094T3
(es)
*
|
1992-12-29 |
1999-03-16 |
Genentech Inc |
Tratamiento de la enfermedad inflamatoria de los intestinos con inhibidores del interferon-gamma.
|
US20030059428A1
(en)
*
|
1993-02-26 |
2003-03-27 |
Boris Skurkovich |
Treatment of autoimmune diseases
|
US20030228310A1
(en)
*
|
1996-12-23 |
2003-12-11 |
Advanced Biotherapy, Inc. |
Treatment of skin diseases
|
US20030223995A1
(en)
*
|
1996-12-23 |
2003-12-04 |
Advanced Biotherapy, Inc. |
Treatment of pemphigus vulgaris
|
US20030086925A1
(en)
*
|
1996-12-23 |
2003-05-08 |
Advanced Biotherapy, Inc. |
Treatment of autoimmune diseases
|
DE69829995T2
(de)
*
|
1997-12-01 |
2006-02-23 |
Fang, Fang, San Diego |
Multivalente rekombinante antikörper zur behandlung von hrv infektionen
|
US20030035798A1
(en)
*
|
2000-08-16 |
2003-02-20 |
Fang Fang |
Humanized antibodies
|
JP2002531466A
(ja)
*
|
1998-12-01 |
2002-09-24 |
プロテイン デザイン ラブス, インコーポレイテッド |
γ−インターフェロンに対するヒト化抗体
|
ES2251248T3
(es)
*
|
1998-12-09 |
2006-04-16 |
Protein Design Labs, Inc. |
Uso de anticuerpos contra il-12 para tratar la psoriasis.
|
US20040002068A1
(en)
|
2000-03-01 |
2004-01-01 |
Corixa Corporation |
Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
|
US7087726B2
(en)
*
|
2001-02-22 |
2006-08-08 |
Genentech, Inc. |
Anti-interferon-α antibodies
|
WO2003062370A2
(en)
*
|
2001-07-19 |
2003-07-31 |
Perlan Therapeutics, Inc. |
Multimeric proteins and methods of making and using same
|
US7084257B2
(en)
|
2001-10-05 |
2006-08-01 |
Amgen Inc. |
Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
|
SG159381A1
(en)
|
2001-10-10 |
2010-03-30 |
Novo Nordisk As |
Remodeling and glycoconjugation of peptides
|
EP2298354B1
(de)
|
2001-10-10 |
2014-03-19 |
ratiopharm GmbH |
Neumodulierung und Glykokonjugation von Interferon-beta
|
US7244592B2
(en)
|
2002-03-07 |
2007-07-17 |
Dyax Corp. |
Ligand screening and discovery
|
PT1482973E
(pt)
|
2002-03-15 |
2009-11-20 |
Schering Corp |
Métodos de modulação dos receptores cd200
|
CA2486147A1
(en)
*
|
2002-05-17 |
2003-11-27 |
Protein Design Labs, Inc. |
Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies
|
US20040052791A1
(en)
*
|
2002-05-22 |
2004-03-18 |
Rolf Ehrhardt |
Treatment of Crohn's disease or psoriasis using anti-interferon gamma antibodies
|
US20050019323A1
(en)
*
|
2002-05-22 |
2005-01-27 |
Protein Design Labs, Inc. |
Treatment of Crohn's disease or psoriasis using anti-interferon gamma antibodies
|
US20040052790A1
(en)
*
|
2002-09-18 |
2004-03-18 |
Advanced Biotherapy, Inc. |
Treatment of schizophrenia
|
US7217797B2
(en)
|
2002-10-15 |
2007-05-15 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
US7361740B2
(en)
|
2002-10-15 |
2008-04-22 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
US7365168B2
(en)
*
|
2002-10-15 |
2008-04-29 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
AU2003285874A1
(en)
*
|
2002-10-16 |
2004-05-04 |
Amgen Inc. |
HUMAN ANTI-IFN-Gamma NEUTRALIZING ANTIBODIES AS SELECTIVE IFN-Gamma PATHWAY INHIBITORS
|
CA2502668C
(en)
*
|
2002-10-17 |
2013-07-30 |
Amgen Inc. |
Fully human antibody fab fragments with human interferon-gamma neutralizing activity
|
JP2006520584A
(ja)
|
2002-11-08 |
2006-09-14 |
アブリンクス エン.ヴェー. |
安定化単一ドメイン抗体
|
WO2004045532A2
(en)
|
2002-11-15 |
2004-06-03 |
Chiron Corporation |
Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
|
WO2004058178A2
(en)
|
2002-12-23 |
2004-07-15 |
Schering Corporation |
Uses of mammalian cytokine; related reagents
|
ATE440864T1
(de)
|
2003-03-10 |
2009-09-15 |
Schering Corp |
Verwendung von il-23-antagonisten; verwandte reagenzien
|
CN1798767B
(zh)
*
|
2003-04-10 |
2011-02-16 |
晶面生物技术公司 |
通过诱变来改变抗体对FcRn的结合亲和力或血清半衰期
|
JP2007531707A
(ja)
*
|
2003-10-15 |
2007-11-08 |
ピーディーエル バイオファーマ, インコーポレイテッド |
IGの重鎖定常領域の位置250、314および/または428の変異誘発によるFc融合タンパク質血清半減期の改変
|
NZ549040A
(en)
|
2004-02-17 |
2009-07-31 |
Schering Corp |
Use for interleukin-33 (IL33) and the IL-33 receptor complex
|
JP5223072B2
(ja)
|
2004-04-02 |
2013-06-26 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
avβ5インテグリンに関連のある疾患を治療および予防するための方法および組成物
|
US7794713B2
(en)
|
2004-04-07 |
2010-09-14 |
Lpath, Inc. |
Compositions and methods for the treatment and prevention of hyperproliferative diseases
|
US20050276806A1
(en)
*
|
2004-06-15 |
2005-12-15 |
Advanced Biotherapy, Inc. |
Treatment of autism
|
TWI363091B
(en)
|
2004-12-20 |
2012-05-01 |
Schering Corp |
Uses of mammalian cytokine; related reagents
|
AU2006208226A1
(en)
*
|
2005-01-24 |
2006-08-03 |
Amgen Inc. |
Humanized anti-amyloid antibody
|
ES2381203T3
(es)
|
2005-01-27 |
2012-05-24 |
Novimmune Sa |
Anticuerpos anti-interferón gamma humanos y métodos de uso de los mismos
|
KR101374454B1
(ko)
*
|
2005-03-31 |
2014-03-17 |
추가이 세이야쿠 가부시키가이샤 |
회합제어에 의한 폴리펩티드 제조방법
|
WO2007016240A2
(en)
*
|
2005-07-28 |
2007-02-08 |
Novartis Ag |
Use of antibody to m-csf
|
EP1913027B1
(de)
*
|
2005-07-28 |
2015-03-04 |
Novartis AG |
M-csf-spezifische monoklonale antikörper und anwendungen davon
|
EP1933869B1
(de)
|
2005-09-01 |
2009-10-14 |
Schering Corporation |
Verwendung von il-23 und il-17-antagonisten zur behandlung von autoimmuner entzündlicher augenerkrankung
|
US20090155850A1
(en)
*
|
2005-10-28 |
2009-06-18 |
The Florida International University Board Of Trustees |
Horse:Human Chimeric Antibodies
|
EP2006381B1
(de)
*
|
2006-03-31 |
2016-02-03 |
Chugai Seiyaku Kabushiki Kaisha |
Verfahren zur kontrolle der blut-pharmakokinetik von antikörpern
|
EP4218801A3
(de)
|
2006-03-31 |
2023-08-23 |
Chugai Seiyaku Kabushiki Kaisha |
Antikörpermodifizierungsverfahren zur reinigung eines bispezifischen antikörpers
|
TWI395754B
(zh)
|
2006-04-24 |
2013-05-11 |
Amgen Inc |
人類化之c-kit抗體
|
US7862812B2
(en)
|
2006-05-31 |
2011-01-04 |
Lpath, Inc. |
Methods for decreasing immune response and treating immune conditions
|
EP2420252A1
(de)
*
|
2006-08-04 |
2012-02-22 |
Novartis AG |
EPHB3-spezifischer Antikörper und Verwendungen davon
|
CA2661023C
(en)
|
2006-08-18 |
2017-08-15 |
Novartis Ag |
Prlr-specific antibody and uses thereof
|
RU2460541C2
(ru)
|
2006-10-27 |
2012-09-10 |
Лпат, Инк. |
Композиции и способы связывания сфингозин-1-фосфата
|
CA2667706A1
(en)
*
|
2006-10-27 |
2008-05-08 |
Lpath, Inc. |
Compositions and methods for treating ocular diseases and conditions
|
EA200900767A1
(ru)
|
2006-12-07 |
2009-12-30 |
Новартис Аг |
Антагонистические антитела против ephb3
|
PE20130588A1
(es)
*
|
2007-02-02 |
2013-05-21 |
Amgen Inc |
Hepcidina, antagonistas de la hepcidina y metodos de uso
|
EP2417974A1
(de)
|
2007-02-28 |
2012-02-15 |
Schering Corporation |
Kombinationstherapie zur Behandlung von Immunerkrankungen
|
EP2164992B1
(de)
*
|
2007-05-30 |
2016-05-04 |
Lpath, Inc. |
Zusammensetzungen und verfahren zur bindung von lysophosphatidinsäure
|
US9163091B2
(en)
*
|
2007-05-30 |
2015-10-20 |
Lpath, Inc. |
Compositions and methods for binding lysophosphatidic acid
|
US7709215B2
(en)
|
2007-06-01 |
2010-05-04 |
Cytonics Corporation |
Method for diagnosing and treating acute joint injury
|
SI2158315T1
(sl)
|
2007-06-25 |
2016-05-31 |
Esbatech, An Alcon Biomedical Research Unit Llc |
Postopki za spreminjanje protiteles in spremenjena protitelesa z izboljšanimi funkcionalnimi lastnostmi
|
SG193868A1
(en)
|
2007-09-26 |
2013-10-30 |
Chugai Pharmaceutical Co Ltd |
Modified antibody constant region
|
PL2202245T3
(pl)
|
2007-09-26 |
2017-02-28 |
Chugai Seiyaku Kabushiki Kaisha |
Sposób modyfikowania punktu izoelektrycznego przeciwciała poprzez podstawienie aminokwasu w cdr
|
US8361465B2
(en)
|
2007-10-26 |
2013-01-29 |
Lpath, Inc. |
Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents
|
ES2834741T3
(es)
|
2007-12-05 |
2021-06-18 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti-NR10 y uso del mismo
|
EP2261254A3
(de)
|
2007-12-21 |
2011-04-13 |
Amgen, Inc |
Antiamyloide Antikörper und deren Verwendungen
|
US9175078B2
(en)
|
2008-01-25 |
2015-11-03 |
Amgen Inc. |
Ferroportin antibodies and methods of use
|
ES2563483T3
(es)
|
2008-04-11 |
2016-03-15 |
Chugai Seiyaku Kabushiki Kaisha |
Molécula de unión a antígeno capaz de unirse repetidamente a dos o más moléculas de antígeno
|
ES2487846T3
(es)
|
2008-05-01 |
2014-08-25 |
Amgen, Inc. |
Anticuerpos anti-hepcindina y métodos de uso
|
US9650639B2
(en)
|
2008-05-19 |
2017-05-16 |
Advaxis, Inc. |
Dual delivery system for heterologous antigens
|
US9017660B2
(en)
|
2009-11-11 |
2015-04-28 |
Advaxis, Inc. |
Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
|
EP2288379A4
(de)
|
2008-05-19 |
2012-08-08 |
Advaxis |
Doppeltes freisetzungssystem für heterologe antigene
|
TWI440469B
(zh)
*
|
2008-09-26 |
2014-06-11 |
Chugai Pharmaceutical Co Ltd |
Improved antibody molecules
|
KR20110084254A
(ko)
|
2008-10-16 |
2011-07-21 |
사이토닉스 코포레이션 |
척추 및 관절 통증을 탐지하고 치료하는 생체표식 및 방법
|
US8871202B2
(en)
|
2008-10-24 |
2014-10-28 |
Lpath, Inc. |
Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
|
WO2010065921A2
(en)
*
|
2008-12-05 |
2010-06-10 |
Lpath, Inc. |
Antibody design using anti-lipid antibody crystal structures
|
US8401799B2
(en)
*
|
2008-12-05 |
2013-03-19 |
Lpath, Inc. |
Antibody design using anti-lipid antibody crystal structures
|
WO2010098863A1
(en)
*
|
2009-02-26 |
2010-09-02 |
Lpath, Inc. |
Humanized platelet activating factor antibody design using anti-lipid antibody templates
|
EP2826789A1
(de)
|
2009-03-19 |
2015-01-21 |
Chugai Seiyaku Kabushiki Kaisha |
Variante einer konstanten Region eines Antikörpers
|
JP5717624B2
(ja)
|
2009-03-19 |
2015-05-13 |
中外製薬株式会社 |
抗体定常領域改変体
|
WO2010121093A2
(en)
*
|
2009-04-17 |
2010-10-21 |
Lpath, Inc. |
Humanized antibody compositions and methods for binding lysophosphatidic acid
|
WO2010131733A1
(ja)
|
2009-05-15 |
2010-11-18 |
中外製薬株式会社 |
抗axl抗体
|
AU2010275367B2
(en)
|
2009-07-24 |
2015-09-03 |
The Regents Of The University Of California |
Methods and compositions for treating and preventing disease associated with avB5 integrin
|
EP2459594A1
(de)
|
2009-07-31 |
2012-06-06 |
N.V. Organon |
Vollständig menschliche antikörper gegen btla
|
WO2011037158A1
(ja)
|
2009-09-24 |
2011-03-31 |
中外製薬株式会社 |
抗体定常領域改変体
|
US10016617B2
(en)
|
2009-11-11 |
2018-07-10 |
The Trustees Of The University Of Pennsylvania |
Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
|
WO2011094345A1
(en)
|
2010-01-26 |
2011-08-04 |
National Jewish Health |
Methods and compositions for risk prediction, diagnosis, prognosis, and treatment of pulmonary disorders
|
US20110212088A1
(en)
*
|
2010-02-26 |
2011-09-01 |
Sabbadini Roger A |
Anti-paf antibodies
|
WO2011108714A1
(ja)
|
2010-03-04 |
2011-09-09 |
中外製薬株式会社 |
抗体定常領域改変体
|
WO2012138377A2
(en)
|
2010-10-01 |
2012-10-11 |
Trustees Of The University Of Pennsylvania |
The use of listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals
|
MY166429A
(en)
|
2010-11-17 |
2018-06-26 |
Chugai Pharmaceutical Co Ltd |
Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
|
US20140234340A1
(en)
|
2010-11-30 |
2014-08-21 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
|
SG10201609665PA
(en)
|
2011-02-25 |
2017-01-27 |
Chugai Pharmaceutical Co Ltd |
FcɣRIIb-SPECIFIC Fc ANTIBODY
|
EP2683400A4
(de)
|
2011-03-11 |
2014-09-17 |
Advaxis |
Adjuvanzien auf listerien-basis
|
TW201817744A
(zh)
|
2011-09-30 |
2018-05-16 |
日商中外製藥股份有限公司 |
具有促進抗原清除之FcRn結合域的治療性抗原結合分子
|
JP6322411B2
(ja)
|
2011-09-30 |
2018-05-09 |
中外製薬株式会社 |
複数の生理活性を有する抗原の消失を促進する抗原結合分子
|
CN104159919A
(zh)
|
2011-11-23 |
2014-11-19 |
安姆根有限公司 |
使用抗干扰素γ抗体的治疗方法
|
SG11201405605VA
(en)
|
2012-03-12 |
2014-10-30 |
Advaxis Inc |
SUPPRESSOR CELL FUNCTION INHIBITION FOLLOWING <i>LISTERIA</i> VACCINE TREATMENT
|
US20150175979A1
(en)
|
2012-07-23 |
2015-06-25 |
La Jolla Institute For Allergy And Immunology |
Ptprs and proteoglycans in autoimmune disease
|
AR093984A1
(es)
|
2012-12-21 |
2015-07-01 |
Merck Sharp & Dohme |
Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
|
ES2823648T3
(es)
|
2013-04-01 |
2021-05-07 |
Univ California |
Métodos y composiciones para tratar y prevenir enfermedades asociadas con la integrina AVB8
|
EP3035964B1
(de)
|
2013-08-20 |
2020-09-23 |
Merck Sharp & Dohme Corp. |
Behandlung von krebs mit einer kombination aus einem pd-1 antagonisten und dinaciclib
|
AR097306A1
(es)
|
2013-08-20 |
2016-03-02 |
Merck Sharp & Dohme |
Modulación de la inmunidad tumoral
|
CA2922698C
(en)
|
2013-08-29 |
2023-01-03 |
City Of Hope |
Cell penetrating conjugates comprising non-cell penetrating antibodies covalently attached to one or more phosphorothioate nucleic acids
|
JP6534615B2
(ja)
|
2013-09-27 |
2019-06-26 |
中外製薬株式会社 |
ポリペプチド異種多量体の製造方法
|
EP3084003A4
(de)
|
2013-12-17 |
2017-07-19 |
Merck Sharp & Dohme Corp. |
Ifn-gamma-gensignaturbiomarker der tumorreaktion auf pd-1 antagonisten
|
CN105960415A
(zh)
|
2014-02-04 |
2016-09-21 |
辉瑞大药厂 |
用于治疗癌症的pd-1拮抗剂和vegfr抑制剂的组合
|
KR20160108568A
(ko)
|
2014-02-04 |
2016-09-19 |
인사이트 코포레이션 |
암을 치료하기 위한 pd-1 길항제 및 ido1 억제제의 조합
|
EP3145956A1
(de)
|
2014-05-21 |
2017-03-29 |
Pfizer Inc. |
Kombination eines anti-ccr4-antikörpers und eines a4-1bb-agonisten zur behandlung von krebs
|
WO2016004383A1
(en)
|
2014-07-03 |
2016-01-07 |
City Of Hope |
Tumor-selective ctla-4 antagonists
|
JO3663B1
(ar)
|
2014-08-19 |
2020-08-27 |
Merck Sharp & Dohme |
الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
|
AU2015305754B2
(en)
|
2014-08-19 |
2018-10-25 |
Merck Sharp & Dohme Llc |
Anti-tigit antibodies
|
US10695426B2
(en)
|
2014-08-25 |
2020-06-30 |
Pfizer Inc. |
Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
SG11201700841QA
(en)
|
2014-12-19 |
2017-03-30 |
Chugai Pharmaceutical Co Ltd |
Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
|
KR20230044338A
(ko)
|
2014-12-19 |
2023-04-03 |
추가이 세이야쿠 가부시키가이샤 |
항-c5 항체 및 그의 사용 방법
|
WO2016115275A1
(en)
|
2015-01-13 |
2016-07-21 |
City Of Hope |
Ctla4-binding protein peptide-linker masks
|
SG11201705413WA
(en)
|
2015-01-16 |
2017-08-30 |
Hope City |
Cell penetrating antibodies
|
CN107108729A
(zh)
|
2015-02-05 |
2017-08-29 |
中外制药株式会社 |
包含离子浓度依赖性的抗原结合结构域的抗体,fc区变体,il‑8‑结合抗体,及其应用
|
AU2016224409B2
(en)
|
2015-02-27 |
2021-01-28 |
Chugai Seiyaku Kabushiki Kaisha |
Composition for treating IL-6-related diseases
|
EP3265122B1
(de)
|
2015-03-04 |
2022-05-04 |
Merck Sharp & Dohme Corp. |
Kombination aus pembrolizumab und eribulin zur behandlung von triple-negativem brustkrebs
|
CA2978226A1
(en)
|
2015-03-04 |
2016-09-09 |
Merck Sharpe & Dohme Corp. |
Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
|
JP6976854B2
(ja)
|
2015-03-30 |
2021-12-08 |
シティ・オブ・ホープCity of Hope |
機械的にかみ合った複合体
|
US11142587B2
(en)
|
2015-04-01 |
2021-10-12 |
Chugai Seiyaku Kabushiki Kaisha |
Method for producing polypeptide hetero-oligomer
|
SG10202108996PA
(en)
|
2015-05-07 |
2021-09-29 |
Swedish Orphan Biovitrum Ag |
Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of cxcl9 and other biomarkers
|
US11091543B2
(en)
|
2015-05-07 |
2021-08-17 |
Swedish Orphan Biovitrum Ag |
Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications
|
PT3294764T
(pt)
|
2015-05-15 |
2021-02-15 |
Hope City |
Composições de recetores de antigénios quiméricos
|
AU2016271018A1
(en)
|
2015-05-29 |
2017-11-30 |
Dynavax Technologies Corporation |
Combination of a PD-1 antagonist and CPG-C type oligonucleotide for treating cancer
|
TW201718023A
(zh)
|
2015-08-06 |
2017-06-01 |
世代好公司 |
細胞滲透性蛋白質-抗體結合物及使用方法
|
US11453697B1
(en)
|
2015-08-13 |
2022-09-27 |
Merck Sharp & Dohme Llc |
Cyclic di-nucleotide compounds as sting agonists
|
WO2017041004A1
(en)
|
2015-09-02 |
2017-03-09 |
The Regents Of The University Of Colorado, A Body Corporate |
Compositions and methods for modulating t-cell mediated immune response
|
CN108603037B
(zh)
|
2015-12-10 |
2020-11-17 |
希望之城 |
细胞穿透花青偶联抗体
|
EP3399989B1
(de)
|
2015-12-16 |
2023-08-09 |
Merck Sharp & Dohme LLC |
Anti-lag3-antikörper und antigenbindende fragmente
|
JP6847958B2
(ja)
|
2015-12-24 |
2021-03-24 |
コーバス・ファーマシューティカルズ・インコーポレイテッド |
がんの治療方法
|
JP7141336B2
(ja)
|
2015-12-25 |
2022-09-22 |
中外製薬株式会社 |
抗ミオスタチン抗体および使用方法
|
EP3398965A4
(de)
|
2015-12-28 |
2019-09-18 |
Chugai Seiyaku Kabushiki Kaisha |
Verfahren zur förderung der effizienz der reinigung von polypeptid mit fc-region
|
CA3010224A1
(en)
|
2016-01-22 |
2017-07-27 |
Merck Sharp & Dohme Corp. |
Anti-coagulation factor xi antibodies
|
KR20210013777A
(ko)
|
2016-01-25 |
2021-02-05 |
화이자 인코포레이티드 |
암을 치료하기 위한 ox40 작용제 및 4-1bb 작용제 단클론 항체의 조합
|
MX2018010988A
(es)
|
2016-03-14 |
2019-01-21 |
Chugai Pharmaceutical Co Ltd |
Farmaco terapeutico que induce lesion celular para usarse en terapia de cancer.
|
US11230591B2
(en)
|
2016-04-20 |
2022-01-25 |
Merck Sharp & Dohme Corp. |
CMV neutralizing antigen binding proteins
|
EA201892716A1
(ru)
|
2016-06-14 |
2019-05-31 |
Мерк Шарп И Доум Корп. |
Антитела к фактору свертывания xi
|
NL2017267B1
(en)
|
2016-07-29 |
2018-02-01 |
Aduro Biotech Holdings Europe B V |
Anti-pd-1 antibodies
|
NL2017270B1
(en)
|
2016-08-02 |
2018-02-09 |
Aduro Biotech Holdings Europe B V |
New anti-hCTLA-4 antibodies
|
CA3026050A1
(en)
|
2016-08-05 |
2018-02-08 |
Chugai Seiyaku Kabushiki Kaisha |
Composition for prophylaxis or treatment of il-8 related diseases
|
JOP20190055A1
(ar)
|
2016-09-26 |
2019-03-24 |
Merck Sharp & Dohme |
أجسام مضادة ضد cd27
|
MX2019003994A
(es)
|
2016-10-14 |
2019-09-19 |
Merck Sharp & Dohme |
Combinacion de un antagonista de proteina de muerte programada-1 (pd-1) y eribulina para el tratamiento de cancer urotelial.
|
EA201990930A1
(ru)
*
|
2016-10-24 |
2019-11-29 |
|
Способы, композиции и режимы дозирования для лечения или профилактики связанных с интерфероном-гамма заболеваний
|
EP3532101B1
(de)
|
2016-10-28 |
2021-12-08 |
Astute Medical, Inc. |
Verwendung von antikörpern gegen timp-2 zur verbesserung der nierenfunktion
|
EP3538101B1
(de)
|
2016-11-14 |
2024-06-19 |
Virginia Commonwealth University |
Inhibitoren von krebs und/oder metastasis
|
AU2018252546A1
(en)
|
2017-04-13 |
2019-10-10 |
Sairopa B.V. |
Anti-SIRPα antibodies
|
EP3620531A4
(de)
|
2017-05-02 |
2021-03-17 |
National Center of Neurology and Psychiatry |
Verfahren zur vorhersage und beurteilung der therapeutischen wirkung bei erkrankungen im zusammenhang mit il-6 und neutrophilen
|
JOP20190260A1
(ar)
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
RU2019138507A
(ru)
|
2017-05-02 |
2021-06-02 |
Мерк Шарп И Доум Корп. |
Составы антител против lag3 и совместные составы антител против lag3 и антител против pd-1
|
JOP20190256A1
(ar)
|
2017-05-12 |
2019-10-28 |
Icahn School Med Mount Sinai |
فيروسات داء نيوكاسل واستخداماتها
|
JP6889328B2
(ja)
|
2017-07-31 |
2021-06-18 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
三次元構造に基づくヒト化方法
|
WO2019067015A1
(en)
|
2017-09-29 |
2019-04-04 |
City Of Hope |
RECEPTORS OF CHIMERIC ANTIGENS AND BISPECIFIC ANTIBODIES FOR THE TREATMENT OF COAT CELL LYMPHOMA
|
JP7194481B2
(ja)
|
2017-11-17 |
2022-12-22 |
メルク・シャープ・アンド・ドーム・エルエルシー |
免疫グロブリン様転写産物3(ilt3)に特異的な抗体およびその使用
|
WO2019148412A1
(en)
|
2018-02-01 |
2019-08-08 |
Merck Sharp & Dohme Corp. |
Anti-pd-1/lag3 bispecific antibodies
|
CN112334485A
(zh)
|
2018-04-06 |
2021-02-05 |
百进生物科技公司 |
抗-四次穿膜蛋白33药剂及其组合物以及制备和使用方法
|
CN112638478A
(zh)
|
2018-06-29 |
2021-04-09 |
希望之城公司 |
用于治疗某些自身免疫病症的cd6靶向性嵌合抗原受体
|
CN112867503A
(zh)
|
2018-08-24 |
2021-05-28 |
希望之城 |
掩蔽的细胞因子缀合物
|
US20210393740A1
(en)
|
2018-09-19 |
2021-12-23 |
La Jolla Institute For Immunology |
Ptprs and proteoglycans in rheumatoid arthritis
|
CN113365697B
(zh)
|
2018-09-25 |
2024-07-19 |
百进生物科技公司 |
抗tlr9药剂和组合物及其制备方法和使用方法
|
JP2022512346A
(ja)
|
2018-12-18 |
2022-02-03 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
レプチン受容体、gdf8、およびアクチビンaに対するアンタゴニストを使用して、体重および除脂肪筋肉量を増やすための組成物および方法
|
US20220370606A1
(en)
|
2018-12-21 |
2022-11-24 |
Pfizer Inc. |
Combination Treatments Of Cancer Comprising A TLR Agonist
|
MA55965A
(fr)
|
2019-05-13 |
2022-03-23 |
Regeneron Pharma |
Combinaison d'inhibiteurs pd-1 et d'inhibiteurs lag-3 pour une efficacité améliorée dans le traitement du cancer
|
US20220241412A1
(en)
|
2019-05-24 |
2022-08-04 |
Pfizer Inc. |
Combination therapies using cdk inhibitors
|
JP2022533833A
(ja)
|
2019-05-24 |
2022-07-26 |
ファイザー・インク |
Cdk阻害剤を使用した組合せ療法
|
MA54975B1
(fr)
|
2019-06-11 |
2023-08-31 |
Regeneron Pharma |
Anticorps anti-pcrv qui se lient à pcrv, compositions comprenant des anticorps anti-pcrv, et leurs méthodes d'utilisation
|
BR112022007971A8
(pt)
|
2019-10-29 |
2023-02-07 |
Eisai R&D Man Co Ltd |
Combinação de antagonista do pd-1, inibidor da tirosina quinase vegfr/fgfr/ret e inibidor da cbp/beta-catenina para o tratamento do câncer
|
US20230076643A1
(en)
|
2019-12-30 |
2023-03-09 |
City Of Hope |
Methods of making and using regulatory t cells and effector t cells having chimeric antigen receptors targeted to cd6, cd19, and/or an il-13r for treatment of autoimmune disorders and cancers
|
CN115427447A
(zh)
|
2020-01-17 |
2022-12-02 |
百进生物科技公司 |
抗tlr7药剂和组合物以及制备和使用其的方法
|
WO2021181233A2
(en)
|
2020-03-09 |
2021-09-16 |
Pfizer Inc. |
Fusion proteins and uses thereof
|
WO2021219871A2
(en)
|
2020-04-30 |
2021-11-04 |
Aduro Biotech Holdings, Europe B.V. |
Anti-cd103 antibodies
|
MX2022014180A
(es)
|
2020-05-13 |
2022-12-02 |
Pfizer |
Metodos, terapias y usos para tratar cancer.
|
BR112022026575A2
(pt)
|
2020-06-25 |
2023-01-17 |
Merck Sharp & Dohme Llc |
Anticorpos de alta afinidade que alvejam tau fosforilado em serina 413
|
WO2022003554A1
(en)
|
2020-07-01 |
2022-01-06 |
Pfizer Inc. |
Biomarkers for pd-1 axis binding antagonist therapy
|
US20230303654A1
(en)
|
2020-08-11 |
2023-09-28 |
City Of Hope |
Compositions and uses of sars-cov-2 targeted chimeric antigen receptor modified nk cells
|
JP2023540490A
(ja)
|
2020-09-02 |
2023-09-25 |
ファーマブシン インコーポレイテッド |
がん患者を治療するためのpd-1拮抗薬及びvegfr-2拮抗薬の併用療法
|
WO2022053990A1
(en)
|
2020-09-14 |
2022-03-17 |
Pfizer Inc. |
Methods, therapies and uses for treating cancer
|
US20220089738A1
(en)
|
2020-09-24 |
2022-03-24 |
Merck Sharp & Dohme Corp. |
Stable Formulations of Programmed Death Receptor 1 (PD-1) Antibodies and Hyaluronidase Variants and Fragments Thereof and Methods of Use Thereof
|
WO2022093640A1
(en)
|
2020-10-30 |
2022-05-05 |
BioLegend, Inc. |
Anti-nkg2c agents and compositions and methods for making and using the same
|
WO2022093641A1
(en)
|
2020-10-30 |
2022-05-05 |
BioLegend, Inc. |
Anti-nkg2a agents and compositions and methods for making and using the same
|
WO2022165001A1
(en)
|
2021-01-29 |
2022-08-04 |
Merck Sharp & Dohme Llc |
Compositions of programmed death receptor 1 (pd-1) antibodies and methods of obtaining the compositions thereof
|
CN112794903B
(zh)
*
|
2021-04-14 |
2021-06-25 |
广州市雷德生物科技有限公司 |
一种特异性结合IFN-γ的抗体及其应用
|
WO2023057882A1
(en)
|
2021-10-05 |
2023-04-13 |
Pfizer Inc. |
Combinations of azalactam compounds with a pd-1 axis binding antagonist for the treatment of cancer
|
WO2023079428A1
(en)
|
2021-11-03 |
2023-05-11 |
Pfizer Inc. |
Combination therapies using tlr7/8 agonist
|
WO2023186756A1
(en)
|
2022-03-28 |
2023-10-05 |
F. Hoffmann-La Roche Ag |
Interferon gamma variants and antigen binding molecules comprising these
|
WO2024020051A1
(en)
|
2022-07-19 |
2024-01-25 |
BioLegend, Inc. |
Anti-cd157 antibodies, antigen-binding fragments thereof and compositions and methods for making and using the same
|
WO2024040114A2
(en)
|
2022-08-18 |
2024-02-22 |
BioLegend, Inc. |
Anti-axl antibodies, antigen-binding fragments thereof and methods for making and using the same
|